keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonate

keyword
https://www.readbyqxmd.com/read/29352368/endocrine-therapy-and-related-issues-in-hormone-receptor-positive-early-breast-cancer-a-roundtable-discussion-by-the-breast-cancer-therapy-expert-group-bcteg
#1
REVIEW
Jame Abraham, Humberto Caldera, Robert Coleman, Anthony Elias, Matthew P Goetz, Muaiad Kittaneh, Elyse Lower, Reshma Mahtani, E Terry Mamounas, Mark Pegram, Hope Rugo, Lee Schwartzberg, Tiffany Traina, Chuck Vogel
PURPOSE: Management of breast cancer is a rapidly evolving field, and, although evidence-based guidelines are available for clinicians to provide direction on critical issues in patient care, clinicians often left to address these issues in the context of community practice situations with their patients. These include the patient's comorbid conditions, actual versus perceived benefit of treatments, patient's compliance as well as financial/reimbursement issues, and long-term tolerability of therapy...
January 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29350069/new-and-developing-pharmacotherapy-for-osteoporosis-in-men
#2
Luigi Gennari, John P Bilezikian
Osteoporosis represents a major health and societal burden in men, as well as in women. However, only a minority of men are screened and treated for osteoporosis and fracture prevention, even after first fracture. Areas covered: This article provides a comprehensive summary of the currently available drugs for osteoporosis in men as well as insights into new and developing pharmacotherapy. Expert opinion: To date, therapeutic approaches to osteoporosis in men remain not as well defined as in women, since antifracture efficacy data are lacking for most approved pharmaceuticals...
January 19, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29349947/incidence-rate-of-atypical-femoral-fracture-after-bisphosphonates-treatment-in-korea
#3
Young Kyun Lee, Soyeon Ahn, Kyoung Min Kim, Chang Suk Suh, Kyung Hoi Koo
BACKGROUND: Atypical femoral fracture (AFF) has been high-lightened, because it was associated with the long-term use of bisphosphonate. Comparing western countries, the incidence rate of AFF was unclear in East Asian patients. Our purposes were to estimate the incidence rate of radiologically defined AFF in Korea, and to determine the association between occurrence of AFF and long-term use of bisphosphonate. METHODS: We conducted a hospital-based, retrospective cohort study in patients aged ≥ 45 years, who took bisphosphonate...
January 29, 2018: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/29349663/ibandronate-metal-complexes-solution-behavior-and-antiparasitic-activity
#4
Bruno Demoro, Santiago Rostán, Mauricio Moncada, Zhu-Hong Li, Roberto Docampo, Claudio Olea Azar, Juan Diego Maya, Julia Torres, Dinorah Gambino, Lucía Otero
To face the high costs of developing new drugs, researchers in both industry and academy are looking for ways to repurpose old drugs for new uses. In this sense, bisphosphonates that are clinically used for bone diseases have been studied as agents against Trypanosoma cruzi, causative parasite of Chagas disease. In this work, the development of first row transition metal complexes (M = Co2+, Mn2+, Ni2+) with the bisphosphonate ibandronate (iba, H4iba representing the neutral form) is presented. The in-solution behavior of the systems containing iba and the selected 3d metal ions was studied by potentiometry...
January 18, 2018: Journal of Biological Inorganic Chemistry: JBIC
https://www.readbyqxmd.com/read/29346675/in-search-of-the-best-xenogeneic-material-for-a-paediatric-conduit-an-experimental-study
#5
Irina Y Zhuravleva, Nataliya R Nichay, Yuriy Y Kulyabin, Tatyana P Timchenko, Alexander A Korobeinikov, Yuliya F Polienko, Svetlana S Shatskaya, Elena V Kuznetsova, Alexey V Voitov, Alexander V Bogachev-Prokophiev, Alexander M Karaskov
OBJECTIVES: The development of calcification-resistant bioprosthetic materials is a very important challenge for paediatric surgery. The subcutaneous implantation in rats is the well-known first-stage model for this kind of research. Using this model, we aimed to compare calcification of the porcine aortic wall and bovine pericardium and jugular vein wall cross-linked with glutaraldehyde (GA) and ethylene glycol diglycidyl ether (DE). We also determined the efficacy of DE-preserved tissue modification with 2-(2-carboxyethylamino)ethylidene-1,1-bisphosphonic acid (CEABA)...
January 15, 2018: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/29344807/inhibition-of-bone-resorption-by-bisphosphonates-interferes-with-orthodontically-induced-midpalatal-suture-expansion-in-mice
#6
Till Koehne, Bärbel Kahl-Nieke, Michael Amling, Heike Korbmacher-Steiner
OBJECTIVES: Craniofacial sutures are important growth sites for skull development and are sensitive to mechanical stress. In order to determine the role of bone resorption in stress-mediated sutural bone growth, midpalatal suture expansion was performed in mice receiving alendronate, an anti-resorptive bisphosphonate. MATERIALS AND METHODS: The midpalatal sutures of 8-week-old C57BL/6 mice were expanded by orthodontic wires over the period of 2 weeks. Mice with maxillary expansion without drug treatment as well as untreated animals served as controls...
January 18, 2018: Clinical Oral Investigations
https://www.readbyqxmd.com/read/29344793/the-role-of-bone-secreted-factors-in-burn-induced-muscle-cachexia
#7
REVIEW
Gordon L Klein
PURPOSE OF REVIEW: Burn injury results in resorptive bone loss, failure to make new bone, and muscle protein breakdown resulting in cachexia. The purpose of this review is to examine the relationship between bone loss and muscle atrophy in burn injury with a view to understanding the process at work and how it may apply to other conditions that have similar features. RECENT FINDINGS: We present data suggesting that the use of bisphosphonates in the first 10 days following the burn prevents not only the resorptive bone loss but also the muscle wasting...
January 17, 2018: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/29344730/skeletal-dissemination-in-paget-s-disease-of-the-spine
#8
REVIEW
Tim Rolvien, Sebastian Butscheidt, Jozef Zustin, Michael Amling
PURPOSE: Paget's disease of bone (PDB) is a common skeletal disorder that is associated with locally increased bone turnover, skeletal deformity and pain. We report a case of skeletal dissemination in PDB of the spine. METHODS: Case report. RESULTS: A 46-year-old former professional athlete suffered from disseminated PDB throughout the spine and hips after various surgical interventions including spondylodesis, bone grafting and bone morphogenetic protein (rhBMP-2) administration...
January 17, 2018: European Spine Journal
https://www.readbyqxmd.com/read/29344330/developments-in-rare-bone-diseases-and-mineral-disorders
#9
REVIEW
Siobhan Bacon, Rachel Crowley
In the last decade, there have been a number of significant advances made in the field of rare bone diseases. In this review, we discuss the expansion of the classification system for osteogenesis imperfecta (OI) and the resultant increase in therapeutic options available for management of OI. Bisphosphonates remain the most widely used intervention for OI, although the effect on fracture rate reduction is equivocal. We review the other therapies showing promising results, including denosumab, teriparatide, sclerostin, transforming growth factor β inhibition and gene targeted approaches...
January 2018: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/29342839/calcium-phosphates-as-delivery-systems-for-bisphosphonates
#10
REVIEW
Adriana Bigi, Elisa Boanini
Bisphosphonates (BPs) are the most utilized drugs for the treatment of osteoporosis, and are usefully employed also for other pathologies characterized by abnormally high bone resorption, including bone metastases. Due to the great affinity of these drugs for calcium ions, calcium phosphates are ideal delivery systems for local administration of BPs to bone, which is aimed to avoid/limit the undesirable side effects of their prolonged systemic use. Direct synthesis in aqueous medium and chemisorptions from solution are the two main routes proposed to synthesize BP functionalized calcium phosphates...
January 13, 2018: Journal of Functional Biomaterials
https://www.readbyqxmd.com/read/29340971/denosumab-or-oral-bisphosphonates-in-primary-osteoporosis-a-real-life-study
#11
E Cairoli, S Palmieri, G Goggi, L Roggero, M Arosio, I Chiodini, C Eller-Vainicher
PURPOSE: To compare the response to denosumab (DMAb) therapy with that of oral bisphosphonate (BISPH) treatment in postmenopausal women with primary osteoporosis (PO). METHODS: In this retrospective study, we compared data of 75 PO female patients treated for 24 months with DMab (DMAb Group, age 72.6 ± 8.9 years) with those of 75 PO patients treated with oral bisphosphonates (BISPH Group), matched for age, body mass index, femoral bone mineral density (BMD), prevalent fragility fractures and familiar history of hip fracture...
January 16, 2018: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/29340346/effects-of-local-drug-and-chemical-compound-delivery-on-bone-regeneration-around-dental-implants-in-animal-models-a-systematic-review-and-meta-analysis
#12
Ali Alenezi, Bruno Chrcanovic, Ann Wennerberg
PURPOSE: One of the suggested methods for enhancing osseointegration is the local application of drug agents around implant surfaces. The aim of this review was to evaluate the methods most commonly used for local drug and chemical compound delivery to implant sites and assess their influence on osseointegration. MATERIALS AND METHODS: An electronic search was undertaken in three databases (PubMed, Scopus, Embase). The search was limited to animal experiments using endosseous implants combined with local drug delivery systems...
January 2018: International Journal of Oral & Maxillofacial Implants
https://www.readbyqxmd.com/read/29339529/management-of-endocrine-disease-atypical-femoral-fractures-risks-and-benefits-of-long-term-treatment-of-osteoporosis-with-anti-resorptive-therapy
#13
Robert Adler
Modern osteoporosis treatment began in the mid-1990's with the approval of amino-bisphosphonates, anti-resorptive agents that have been shown to decrease osteoporotic fracture risk by about half. In 2005, the first cases of atypical femoral fractures (AFF), occurring in the shaft of the femur, were reported. Since then, more cases have been found, leading to great concern among patients and a dramatic decrease in bisphosphonate prescribing. The pathogenesis and incidence of AFF are reviewed herein. Management and an approach to prevention or early detection of AFF are also provided...
January 16, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29338853/atypical-fractures-an-issue-of-concern-or-a-myth
#14
Mohammad Al-Ashqar, Michalis Panteli, Gautam Chakrabarty, Peter V Giannoudis
Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the supracondylar flare of a femur. An increasing pool of evidence supports their association with the prolonged use of bisphosphonates, even though a direct correlation is yet to be proved. The purpose of this review is to encapsulate the current evidence associating bisphosphonate use and the development of AFFs, the clinical features related to their presentation, as well as to report the armamentarium of strategies available in the prevention and treatment of AFFs...
December 16, 2017: Injury
https://www.readbyqxmd.com/read/29337454/-osteoporosis
#15
Brigitte Uebelhart, Serge Ferrari
The risk for a second fracture within two years after a first one is high. Ten years denosumab treatment show favorable results with a risk of early vertebral fractures in patients with prevalent vertebral fractures when treatment is stopped. Teriparatide is more effective than risedronate to prevent vertebral and clinical fractures in high risk patients. Romosozumab acts as an anabolic agent in osteoporosis. Atypical femoral fractures associated with bisphosphonate treatment could be more frequent in patients with particular anatomical features...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29332361/bisphosphonate-associated-orbital-inflammation-is-it-class-specific-side-effect
#16
Kadri Altundag
No abstract text is available yet for this article.
November 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29330102/bisphosphonates-intake-and-its-association-with-changes-of-periarticular-bone-area-and-three-dimensional-shape-data-from-the-osteoarthritis-initiative-oai
#17
Arya Haj-Mirzaian, Ali Guermazi, Frank W Roemer, Mike A Bowes, Philip G Conaghan, Shadpour Demehri
OBJECTIVE: To determine the association between bisphosphonate treatment with the change of periarticular bone area and three-dimensional (3D) shape in participants of the Osteoarthritis Initiative (OAI) study. DESIGN: Using propensity score (PS) matching method in females, 48 bisphosphonate users and 105 non-users, who were matched for OA and osteoporosis related factors were included. Baseline and 24-month MRI-based periarticular bone area and 3D shape measurements were used...
January 9, 2018: Osteoarthritis and Cartilage
https://www.readbyqxmd.com/read/29329484/effects-of-teriparatide-compared-with-risedronate-on-the-risk-of-fractures-in-subgroups-of-postmenopausal-women-with-severe-osteoporosis-the-vero-trial
#18
Piet Geusens, Fernando Marin, David L Kendler, Luis A Russo, Cristiano A F Zerbini, Salvatore Minisola, Jean Jacques Body, Eric Lespessailles, Susan L Greenspan, Alicia Bagur, Jan J Stepan, Péter Lakatos, Enrique Casado, Rüdiger Moericke, Pedro López-Romero, Astrid Fahrleitner-Pammer
The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), and BMD T-score ≤-1.5. Patients were treated with either s.c. daily teriparatide 20 μg or oral weekly risedronate 35 mg. As previously reported, the risk of new VFx and clinical fractures (a composite of clinical VFx and non vertebral fragility fractures [NVFFx]) was statistically significantly reduced with teriparatide compared with risedronate...
January 12, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29325766/duration-of-treatment-with-bisphosphonates-at-the-time-of-osteonecrosis-of-the-jaw-onset-in-patients-with-rheumatoid-arthritis-review
#19
Hugo Compain, Alexandre Berquet, Ludwig-Stanislas Loison-Robert, Victorin Ahossi, Narcisse Zwetyenga
INTRODUCTION: Rheumatoid arthritis (RA) is a frequent and co-morbid condition. One of the main complications is induced osteoporosis. Treatments related to this complication significantly modify oral and implant management. Affected patients represent a population at intermediate risk of osteonecrosis of the jaw (ONJ). The objective was to search the literature for durations of treatment with bisphosphonates at the time of ONJ occurrence in patients with RA in order to obtain an average duration...
January 8, 2018: Journal of Stomatology, Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/29323712/paradoxical-side-effects-of-bisphosphonates-on-the-skeleton-what-do-we-know-and-what-can-we-do
#20
REVIEW
Jorge William Vargas-Franco, Beatriz Castaneda, Françoise Rédiní, David Francisco Gómez, Dominique Heymann, Frédéric Lézot
Bisphosphonates are considered the most effective drugs for controlling adult and pediatric osteolytic diseases. Although they have been used successfully for many years, several side effects, such as osteonecrosis of the jaw, delayed dental eruption, atypical femoral fracture and alterations to the bone growth system, have been described. After an overview of nitrogenous bisphosphonate, the purpose of this article is to describe their mechanisms of action and current applications, review the preclinical and clinical evidence of their side effects in the skeleton ("what we know"), and describe current recommendations for preventing and managing these effects ("what we can do")...
January 11, 2018: Journal of Cellular Physiology
keyword
keyword
49305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"